Clusterin silencing restores myoblasts viability and down modulates the inflammatory process in osteoporotic disease.

Abstract

BACKGROUND:

Targeting new molecular pathways leading to Osteoporosis (OP) and Osteoarthritis (OA) is a hot topic for drug discovery. Clusterin (CLU) is a glycoprotein involved in inflammation, proliferation, cell death, neoplastic disease, Alzheimer disease and aging. The present study focuses on the expression and the role of CLU in influencing the decrease of muscle mass and fiber senescence in OP-OA condition.

METHODS:

Vastus lateralis muscle biopsies were collected from 20 women with OP undergoing surgery for fragility hip fracture and 20 women undergoing arthroplasty for hip osteoarthritis.

RESULTS:

We found an overexpression of CLU in degenerated fibers in OP closely correlated with interleukin 6 (IL6) and histone H4 acetylation level. Conversely, in OA muscle tissues we observed a weak expression of CLU but no nuclear histone H4 acetylation. Ex vivo studies on isolated human myoblasts confirmed CLU overexpression in OP as compared to OA (p < 0.001). CLU treatment of isolated OP and OA myoblasts showed: modulation of proliferation, morphological changes, increase of histone H4 acetylation and induction of myogenin (MYOG) activation in OP myoblast only. In OP condition, functional knockdown of CLU by siRNA restores proliferative myoblasts capability and tissue damage repair, carried out by an evident upregulation of Transglutaminase 2 (TGM2). We also observed downmodulation of CX3CR1 expression with consequent impairing of the inflammatory infiltrate recruitment.

CONCLUSIONS:

Results obtained suggest a potential role of CLU in OP by influencing myoblasts terminal differentiation, epigenetic regulation of muscle cell differentiation and senescence. Moreover, CLU silencing points out its role in the modulation of tissue damage repair and inflammation, proposing it as a new diagnostic marker for muscle degeneration and a potential target for specific therapeutic intervention in OP related sarcopenia.

• Authors: S Pucci, C Greggi, C Polidoro, M C Piro, M Celi, M Feola, E Gasbarra, R Iundusi, F Mastrangeli, G Novelli, A Orlandi, U Tarantino
• Journal: Journal of translational medicine (J Transl Med) Vol. 17 Issue 1 Pg. 118 (04 10 2019) ISSN: 1479-5876 [Electronic] England
• PMID: 30967152 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• CX3C Chemokine Receptor 1
• CX3CR1 protein, human
• Clusterin
• Histones
• Interleukin-6
• Myogenin
• Recombinant Proteins
• DNA

Topics

• Acetylation (drug effects)
• Adult
• Aged
• Aged, 80 and over
• CX3C Chemokine Receptor 1 (metabolism)
• Cell Proliferation (drug effects)
• Cell Survival (drug effects)
• Clusterin (genetics, metabolism)
• DNA (metabolism)
• Female
• Gene Silencing (drug effects)
• Histones (metabolism)
• Humans
• Inflammation (complications, pathology)
• Interleukin-6 (metabolism)
• Muscle, Skeletal (metabolism, pathology)
• Myoblasts (drug effects, metabolism, pathology)
• Myogenin (metabolism)
• Osteoarthritis, Hip (metabolism, pathology)
• Osteoporosis (complications, metabolism, pathology)
• Recombinant Proteins (pharmacology)